Глава 6. Когда белое становится черным: депрессия и тревожность
1. Whiteford, H. A., et al., “Global Burden of Disease Attributable to Mental and Substance Use Disorders: Findings from the Global Burden of Disease Study 2010,” Lancet 382, no. 9904 (November 9, 2013): 1575–1586, doi:10.1016/S0140–6736 (13) 61611–6.
2. Verhoeven, J. E., et al., “Anxiety Disorders and Accelerated Cellular Ageing,” British Journal of Psychiatry 206, no. 5 (May 2015): 371–378.
3. Cai, N., et al., “Molecular Signatures of Major Depression,” Current Biology 25, no. 9 (May 4, 2015): 1146–1156, doi:10.1016/j.cub.2015.03.008.
4. Verhoeven, J. E., et al., “Major Depressive Disorder and Accelerated Cellular Aging: Results from a Large Psychiatric Cohort Study,” Molecular Psychiatry 19, no. 8 (August 2014): 895–901, doi:10.1038/mp. 2013.151.
5. Mamdani, F., et al., “Variable Telomere Length Across Post-Mortem Human Brain Regions and Specific Reduction in the Hippocampus of Major Depressive Disorder,” Translational Psychiatry 5 (September 15, 2015): e636, doi:10.1038/tp.2015.134.
6. Zhou, Q. G., et al., “Hippocampal Telomerase Is Involved in the Modulation of Depressive Behaviors,” Journal of Neuroscience 31, no. 34 (August 24, 2011): 12258–12269, doi:10.1523/JNEUROSCI.0805–11.2011.
7. Wolkowitz, O. M., et al., “PBMC Telomerase Activity, but Not Leukocyte Telomere Length, Correlates with Hippocampal Volume in Major Depression,” Psychiatry Research 232, no. 1 (April 30, 2015): 58–64, doi:10.1016/j.pscychresns.2015.01.007.
8. Darrow, S. M. et al., “The Association between Psychiatric Disorders and Telomere Length: A Meta-analysis Involving 14,827 Persons,” Psychosomatic Medicine 78, no. 7 (September 2016): 776–87, doi:10.1097/ PSY.0000000000000356.
9. Cai et al., “Molecular Signatures of Major Depression.” (See #3 above.)
10. Verhoeven, J. E., et al., “The Association of Early and Recent Psychosocial Life Stress with Leukocyte Telomere Length,” Psychosomatic Medicine 77, no. 8 (October 2015): 882–891, doi:10.1097/PSY.0000000000000226.
11. Verhoeven, J. E., et al., “Major Depressive Disorder and Accelerated Cellular Aging: Results from a Large Psychiatric Cohort Study,” Molecular Psychiatry 19, no. 8 (August 2014): 895–901, doi:10.1038/mp.2013.151.
12. Ibid.
13. Cai et al., “Molecular Signatures of Major Depression.” (See #3 above.)
14. Eisendrath, S. J., et al., “A Preliminary Study: Efficacy of Mindfulness-Based Cognitive Therapy Versus Sertraline as First-Line Treatments for Major Depressive Disorder,” Mindfulness 6, no. 3 (June 1, 2015): 475–482, doi:10.1007/s12671–014–0280–8; and Kuyken, W., et al., “The Effectiveness and Cost-Effectiveness of Mindfulness-Based Cognitive Therapy Compared with Maintenance Antidepressant Treatment in the Prevention of Depressive Relapse/Recurrence: Results of a Randomised Controlled Trial (the PREVENT Study),” Health Technology Assessment 19, no. 73 (September 2015): 1–124, doi:10.3310/hta19730.
15. Teasdale, J. D., et al., “Prevention of Relapse/Recurrence in Major Depression by Mindfulness-Based Cognitive Therapy,” Journal of Consulting and Clinical Psychology 68, no. 4 (August 2000): 615–623.
16. Teasdale, J., M. Williams, and Z. Segal, The Mindful Way Workbook: An 8-Week Program to Free Yourself from Depression and Emotional Distress (New York: Guilford Press, 2014).
17. Wolfson, W. & Epel, E. (2006). “Stress, post-traumatic growth, and leukocyte aging.” Poster presentation at the American Psychosomatic Society 64th Annual Meeting, Denver, Colorado, Abstract 1476.
18. Segal, Z., J. M. G. Williams, and J. Teasdale, Mindfulness-Based Cognitive Therapy for Depression, 2nd ed. (New York: Guilford Press, 2013): 74–75. (The Three minute breathing space is part of the MBCT program. Our breathing break is a modified version).
19. Bai, Z., et al., “Investigating the Effect of Transcendental Meditation on Blood Pressure: A Systematic Review and Meta-analysis,” Journal of Human Hypertension 29, no. 11 (November 2015): 653–662. doi:10.1038/ jhh.2015.6; and Cernes, R., and R. Zimlichman, “RESPeRATE: The Role of Paced Breathing in Hypertension Treatment.” Journal of the American Society of Hypertension 9, no. 1 (January 2015): 38–47, doi:10.1016/ j.jash.2014.10.002.
20. Morgan, N., M. R. Irwin, M. Chung, and C. Wang, “The Effects of Mind-Body Therapies on the Immune System: Meta-analysis,” PLOS ONE 9, no. 7 (2014): e100903, doi:10.1371/journal.pone.0100903.
21. Conklin, Q., et al., “Telomere Lengthening After Three Weeks of an Intensive Insight Meditation Retreat,” Psychoneuroendocrinology 61 (November 2015): 26–27, doi:10.1016/j.psyneuen.2015.07.462.
22. Epel, E., et al. “Meditation and Vacation Effects Impact Disease-Associated Molecular Phenotypes,” Translational Psychiatry (August 2016): 6, e880, doi: 10.1038/tp.2016.164.
23. Kabat-Zinn, J., Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness, rev. ed. (New York: Bantam Books, 2013).
24. Lengacher, C. A., et al., “Influence of Mindfulness-Based Stress Reduction (MBSR) on Telomerase Activity in Women with Breast Cancer (BC),” Biological Research for Nursing 16, no. 4 (October 2014): 438–447, doi:10.1177/1099800413519495.
25. Carlson, L. E., et al., “Mindfulness-Based Cancer Recovery and Supportive-Expressive Therapy Maintain Telomere Length Relative to Controls in Distressed Breast Cancer Survivors,” Cancer 121, no. 3 (February 1, 2015): 476–484, doi:10.1002/cncr.29063.
26. Black, D. S., et al., “Yogic Meditation Reverses NF– B and IRF-Related Transcriptome Dynamics in Leukocytes of Family Dementia Caregivers in a Randomized Controlled Trial,” Psychoneuroendocrinology 38, no. 3 (March 2013): 348–355, doi:10.1016/j.psyneuen.2012.06.011.
27. Lavretsky, H., et al.,”A Pilot Study of Yogic Meditation for Family Dementia Caregivers with Depressive Symptoms: Effects on Mental Health, Cognition, and Telomerase Activity,” International Journal of Geriatric Psychiatry 28, no. 1 (January 2013): 57–65, doi:10.1002/gps.3790.
28. Desveaux, L., A. Lee, R, Goldstein, and D. Brooks, “Yoga in the Management of Chronic Disease: A Systematic Review and Meta-analysis.” Medical Care 53, no. 7 (July 2015): 653–661, doi:10.1097/ MLR.0000000000000372.
29. Hartley, L., et al., “Yoga for the Primary Prevention of Cardiovascular Disease,” Cochrane Database of Systematic Reviews 5 (May 13, 2014): CD010072, doi:10.1002/14651858.CD010072.pub2.
30. Lu, Y. – H., B. Rosner, G. Chang, and L. M. Fishman, “Twelve-Minute Daily Yoga Regimen Reverses Osteoporotic Bone Loss,” Topics in Geriatric Rehabilitation 32, no. 2 (April 2016): 81–87.
31. Liu, X., et al., “A Systematic Review and Meta-analysis of the Effects of Qigong and Tai Chi for Depressive Symptoms,” Complementary Therapies in Medicine 23, no. 4 (August 2015): 516–534, doi:10.1016/j.ctim.2015.05.001.
32. Freire, M. D., and C. Alves, “Therapeutic Chinese Exercises (Qigong) in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews 7, no. 1 (March 2013): 56–59, doi:10.1016/j.dsx.2013.02.009.
33. Ho, R. T. H., et al., “A Randomized Controlled Trial of Qigong Exercise on Fatigue Symptoms, Functioning, and Telomerase Activity in Persons with Chronic Fatigue or Chronic Fatigue Syndrome,” Annals of Behavioral Medicine 44, no. 2 (October 2012): 160–170, doi:10.1007/s12160–012–9381–6.
34. Ornish D., et al., “Effect of Comprehensive Lifestyle Changes on Telomerase Activity and Telomere Length in Men with Biopsy-Proven Low-Risk Prostate Cancer: 5-Year Follow-Up of a Descriptive Pilot Study,” Lancet Oncology 14, no. 11 (October 2013): 1112–1120, doi: 10.1016/S1470–2045 (13) 70366–8.
